NANOVIRICIDES INC
For the period ended Jun 30, 2024. Filed Sep 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 27, 2024
NNVC$1.42+6.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
| Exhibits · Description · Filed / furnished / incorporated by reference from · Incorporated by reference from exhibit · Date filed | ||||||||
|---|---|---|---|---|---|---|---|---|
| 3.1 · Certificate of Incorporation · Schedule 14C · A · April 23, 2009 | ||||||||
| 2 | Amended and Restated Bylaws | Form 10-Q | 3.1 | February 22, 2010 | ||||
| 3.3 | | Plan of Conversion of NanoViricides, Inc. into NanoViricides, Inc. dated May 22, 2023 | | Form 8-K | | 2.1 | | May 25, 2023 |
| 4.1 | Specimen Common Stock Certificate of the Registrant | Form 10-SB | 4.1 | November 14, 2006 | ||||
| 10.1 | Form of Scientific Advisory Board Agreement | Form 10-SB | 10.5 | November 14, 2006 | ||||
| 10.2 | Amended License Agreement with TheraCour Pharma, Inc. | Form 10-SB | 10.6 | November 14, 2006 | ||||
| 10.3 | Amendment to License Agreement with TheraCour Pharma, Inc. | Form 10-SB | 10.11 | January 17, 2007 | ||||
| 10.4 | Employment Agreement with M Vyas | Form S-1 | 10.7 | November 29, 2019 | ||||
| 10.5 | Agreement of Purchase and Sale between the Registrant and Inno-Haven, LLC | Form 8-K | 10.1 | January 7, 2015 | ||||
| 10.6 | Conversion and Settlement Agreement | Form 8-K | 10.1 | February 13, 2017 | ||||
| 10.7 | Employment Agreement with Anil Diwan | Form 8-K | 10.1 | July 23, 2018 | ||||
| 10.8 | Underwriting with Aegis Capital Corp. dated January 21, 2020 | Form 8-K | 10.1 | January 27, 2020 | ||||
| 10.9 | Form of Settlement Agreement and Mutual Release | Form 8-K | 10.1 | January 28, 2020 | ||||
| 10.10 | Form of Exchange Agreement | Form 8-K | 10.2 | January 28, 2020 | ||||
| 10.11 | Form of Common Stock Purchase Warrant | Form 8-K | 10.3 | January 28, 2020 | ||||
| 10.12 | Director Retainer Agreement between NanoViricides, Inc. and Makarand Jawadekar | Form 8-K | 10.1 | February 11, 2020 | ||||
| 10.13 | Director Retainer Agreement, dated as of May 15, 2020, between NanoViricides, Inc. and Todd Rokita | Form 8-K | 10.1 | May 19, 2020 | ||||
| 10.14 | Form of Securities Purchase Agreement dated May 21, 2020 by and between NanoViricides, Inc. and certain purchasers | Form 8-K | 10.1 | May 22, 2020 | ||||
| 10.15 | Placement Agent Agreement, dated May 21, 2020 by and between among NanoViricides, Inc. Maxim Group LLC and Kingswood Capital Markets, a division of Benchmark Investments, Inc. | Form 8-K | 10.2 | May 22, 2020 | ||||
| 10.16 | Underwriting Agreement with Kingswood Capital Markets, a Division of Benchmark Investments, Inc. dated July 8, 2020. | Form 8-K | 10.1 | July 13, 2020 | ||||
| 10.17 | At Market Issuance Sales Agreement by and between NanoViricides, Inc., B. Riley Securities, Inc. and Kingswood Capital Markets, a division of Benchmark Investments, Inc., dated July 31, 2020 | Form 8-K | 1.1 | August 3, 2020 | ||||
| 10.18 | | Director Retainer Agreement dated November 13, 2020 between NanoViricides, Inc. and Brian Zucker | | Form 8-K | | 10.1 | | November 13, 2020 |
| 10.19 | | License Agreement dated September 7, 2021 between NanoViricides, Inc. and TheraCour Pharma, Inc. | | Form 8-K | | 10.1 | | September 9, 2021 |
| 10.20 | | Extension to Employment Agreement with A. Diwan | | Form 8-K | | 10.2 | | September 9, 2021 |
| 10.21 | | Extension to Employment Agreement with A. Diwan | | Form 8-K | | 10.2 | | October 11, 2022 |
| 10.22 | | License Agreement with Karveer Meditech Private Limited | | Form 8-K | | 10.1 | | March 27, 2023 |
| 10.23 | | Deferred Expense Exchange Agreement between NanoViricides, Inc. and TheraCour Pharma, Inc. | | Form 8-K | | 10.2 | | August 29, 2023 |
| 10.24 | | Convertible Promissory Note between NanoViricides, Inc and TheraCour Pharma, Inc., effective July 19, 2023 | | Form 8-K | | 10.3 | | August 29, 2023 |
| 10.25 | | Extension to Employment Agreement with A. Diwan effective July 1, 2023 | | Form 10-K | | 10.25 | | October 13, 2023 |
| 10.26 | | Extension to CFO Agreement with Meeta Vyas effective July 1, 2023 | | Form 10-K | | 10.26 | | October 13, 2023 |
| 10.27 | | Amendment to License Agreement between NanoViricides, Inc. and TheraCour, dated February 13, 2024 | | Form 8-K | | 10.2 | | February 16, 2024 |
| 10.28 | | Line of Credit Agreement between NanoViricides, Inc. and Dr. Anil R. Diwan, dated November 13, 2023 | | Form 8-K | | 10.3 | | February 16, 2024 |
| 10.29 | | Extension Agreement between the Company and Dr. Anil R. Diwan, dated February 12, 2024 | | Form 8-K | | 10.4 | | February 16, 2024 |
| 10.30 | | Letter from TheraCour Pharma, Inc. | | Form 8-K | | 10.5 | | February 16, 2024 |
| 10.31 | | At Market Issuance Sales Agreement by and between NanoViricides, Inc. and EF Hutton LLC | | Form 8-K | | 1.1 | | April 5, 2024 |
| 10.32 | | Extension of Employment Agreement with Anil Diwan effective July 1, 2024 | | Form 8-K | | 10.1 | | August 9, 2024 |
| 10.33 | | Extension of Employment Agreement with MeetaVyas effective July 1, 2024 | | Form 8-K | | 10.2 | | August 9, 2024 |
| 10.34* | | Amendment to Line of Credit Agreement datedSeptember 22, 2024 | | | | | | |
| 14.1 | Code of Ethics | Form 10-SB | 10.10 | November 14, 2006 | ||||
| 19.1* | | NanoViricides, Inc. Insider Trading Policy effective September 20, 2024 | | | | | | |
| 23 | | Consent of EisnerAmper LLP | | | | | | |
| 31.1 | Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended | |||||||
| 31.2 | Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended | |||||||
| 32.1 | Certification of Chief Executive Officer required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||||||
| 32.2 | Certification of Chief Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||||||
| 101.INS | Inline XBRL Instance Document. | |||||||
| 101.SCH | Inline XBRL Schema Document. | |||||||
| 101.CAL | Inline XBRL Calculation Linkbase Document. | |||||||
| 101.DEF | Inline XBRL Definition Linkbase Document. | |||||||
| 101.LAB | Inline XBRL Label Linkbase Document. | |||||||
| 101.PRE | Inline XBRL Presentation Linkbase Document. | |||||||
| 104 | | Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit) | | | | | | |
| | | | | | | | | |
| * | | Filed herewith | | | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.